ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson?s Disease and Movement Disorders

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive results from an 8-week, open-label, single-arm Phase 2 study evaluating an investigational use and safety of pimavanserin as a monotherapy or adjunct to selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) therapy for Parkinson?s disease (PD) patients with depressive symptoms. These results were presented today during a poster session at the 2019 Interna